July 27, 2016 — Penumbra Inc. announced U.S. commercial availability of its latest thrombectomy device, the ACE68 Reperfusion Catheter, part of the fully integrated Penumbra System. The device was launched at the Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting in Boston.
The ACE68 Reperfusion Catheter leverages the latest advancements in tracking technology to deliver maximum aspiration power easily and safely through a large bore reperfusion catheter for extracting thrombus in acute ischemic stroke patients.
Clinical experience with the ACE68 was shared in the Industry Technology Luncheon Symposium by Blaise Baxter, M.D., chief of radiology at Erlanger Hospital in Tennessee and chairman of radiology for the University of Tennessee College of Medicine Chattanooga.
“The tracking technology of the ACE68 Reperfusion Catheter is the most advanced,” said Baxter. “In my clinical experience with the ACE68, I saw the device easily navigate difficult tortuosity that would have challenged other devices. ACE68’s tracking performance, combined with a large aspiration lumen to enable efficient clot removal, make ACE68 the most compelling frontline device in stroke intervention.”
The device was engineered on a new, innovative tracking platform from hub to tip. Featuring a unique coil winding geometry along 16 transitions to create the optimal tracking profile, ACE68 is designed to ensure easy tracking through tortuosity that is typical in acute ischemic stroke patients. ACE68 is powered to extract clots en masse quickly and effectively as part of the fully integrated Penumbra System.
“With the ACE68 Reperfusion Catheter, I can easily deliver full aspiration power to the occlusion,” said Johanna Fifi, M.D., assistant professor of neurology, neurosurgery and radiology at The Mount Sinai Hospital and director of the Endovascular Stroke Program at the Mount Sinai Health System in New York. “The ACE68’s large lumen increases the likelihood of capturing the clot fully within the catheter or the canister, potentially reducing the number of passes to achieve complete revascularization and minimize ENT (embolization to new territory).”
“The ACE68 provides an opportunity to reverse strokes faster and with less expense,” said Adam Arthur, M.D., MPH, FACS, professor, Department of Neurosurgery, UTHSC, Semmes-Murphey Neurologic & Spine Institute. “The larger lumen seems to allow better clot capture, which may reduce the need for adjunctive devices, simplify the procedure and reduce procedure cost — important considerations as hospitals look to expand stroke services.”
For more information: www.penumbrainc.com
January 19, 2026 
